Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTXNASDAQ:NAGENASDAQ:NRIXNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$4.12-1.9%$3.98$2.94▼$10.25$229.65M3.04141,840 shs88,896 shsNAGENiagen Bioscience$11.51-1.8%$8.45$2.31▼$12.07$906.64M1.94846,974 shs632,420 shsNRIXNurix Therapeutics$12.50+2.8%$10.35$8.18▼$29.56$952.95M2.23878,896 shs853,782 shsSYRESpyre Therapeutics$16.62+0.6%$14.20$10.91▼$40.26$1.00B2.78615,660 shs357,659 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-1.90%-4.63%+3.52%-8.85%-33.55%NAGENiagen Bioscience-1.79%+6.38%+31.84%+49.48%+317.03%NRIXNurix Therapeutics+2.80%+17.48%+29.53%-9.81%-25.86%SYRESpyre Therapeutics+0.61%+6.88%+32.85%-14.73%-52.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFHTXFoghorn Therapeutics2.3594 of 5 stars3.62.00.00.02.51.70.6NAGENiagen Bioscience0.8561 of 5 stars2.50.00.00.02.90.00.0NRIXNurix Therapeutics2.1318 of 5 stars4.40.00.00.03.30.80.0SYRESpyre Therapeutics2.4807 of 5 stars3.61.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 3.13Buy$12.13194.30% UpsideNAGENiagen Bioscience 3.00Buy$13.0012.95% UpsideNRIXNurix Therapeutics 2.83Moderate Buy$30.18141.41% UpsideSYRESpyre Therapeutics 3.25Buy$53.40221.30% UpsideCurrent Analyst Ratings BreakdownLatest FHTX, SYRE, NRIX, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.004/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/29/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/23/2025FHTXFoghorn TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025FHTXFoghorn TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$9.004/23/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/9/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $25.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$23.50M9.77N/AN/A($1.83) per share-2.25NAGENiagen Bioscience$107.93M8.40N/AN/AN/A∞NRIXNurix Therapeutics$56.42M16.89N/AN/A$7.44 per share1.68SYRESpyre Therapeutics$890K1,125.60N/AN/A($0.22) per share-75.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$98.43M-$1.36N/AN/AN/A-357.53%N/A-30.98%8/14/2025 (Estimated)NAGENiagen BioscienceN/A$0.1767.71∞N/AN/AN/AN/AN/ANRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-354.85%-53.65%-38.59%7/10/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$3.77N/AN/AN/AN/A-210.01%-44.40%8/6/2025 (Estimated)Latest FHTX, SYRE, NRIX, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/8/2025Q1 2025SYRESpyre Therapeutics-$0.76-$0.74+$0.02-$0.74N/AN/A4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 million3/6/2025Q4 2024FHTXFoghorn Therapeutics-$0.43-$0.30+$0.13-$0.30$8.56 million$2.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A4.774.77NAGENiagen BioscienceN/AN/AN/ANRIXNurix TherapeuticsN/A6.466.46SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%NAGENiagen Bioscience15.41%NRIXNurix TherapeuticsN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics7.58%NAGENiagen Bioscience9.39%NRIXNurix Therapeutics7.40%SYRESpyre Therapeutics15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12055.74 million50.57 millionOptionableNAGENiagen Bioscience12078.77 millionN/AN/ANRIXNurix Therapeutics30076.24 million70.42 millionOptionableSYRESpyre Therapeutics7360.28 million48.24 millionOptionableFHTX, SYRE, NRIX, and NAGE HeadlinesRecent News About These CompaniesSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - Here's What HappenedJune 4 at 3:13 PM | marketbeat.com122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbHJune 3 at 4:16 AM | marketbeat.comWellington Management Group LLP Has $37.35 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)June 1, 2025 | marketbeat.comMillennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 31, 2025 | marketbeat.comAnalysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $53.40May 31, 2025 | americanbankingnews.comWall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should KnowMay 30, 2025 | zacks.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Voloridge Investment Management LLCMay 29, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsMay 29, 2025 | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 28, 2025 | prnewswire.comBNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 27, 2025 | marketbeat.comWoodline Partners LP Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 25, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust CorpMay 21, 2025 | marketbeat.comRTW Investments LP Raises Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 18, 2025 | marketbeat.comPolar Capital Holdings Plc Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 18, 2025 | marketbeat.comProsight Management LP Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 17, 2025 | marketbeat.comJanus Henderson Group PLC Buys 336,209 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 16, 2025 | marketbeat.comHow Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%May 13, 2025 | zacks.comJefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 13, 2025 | marketbeat.comFirst Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 12, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)May 10, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFHTX, SYRE, NRIX, and NAGE Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$4.12 -0.08 (-1.90%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$4.12 +0.00 (+0.12%) As of 06/5/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Niagen Bioscience NASDAQ:NAGE$11.51 -0.21 (-1.79%) As of 06/5/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Nurix Therapeutics NASDAQ:NRIX$12.50 +0.34 (+2.80%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$12.72 +0.22 (+1.75%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Spyre Therapeutics NASDAQ:SYRE$16.62 +0.10 (+0.61%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$15.90 -0.72 (-4.33%) As of 06/5/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
